CEBPB and neoplasm: Notably, in liver cancer, hypomethylation of the C/EBPβ SE further amplifies its own transcription and reshapes the enhancer landscape, thereby driving malignant phenotypes and tumor progression rather than directly impairing anti-tumor immunity (81–83).